ImmunoRad Paris 2025
Tim Illidge
Manchester Cancer Research Center, United Kingdom
Dr Illidge completing undergraduate degree in Biochemistry (BSc, London University, before his medical degree (MB BS) from Guy’s Hospital, London. He trained in clinical oncology in Southampton and tumour immunotherapy formed the basis of his PhD (University of Southampton) with antibodies and radiotherapy combinations. In 1994 he was appointed a Cancer Research UK clinical fellow and in 1997 awarded Young British Cancer researcher of the year followed by a Senior Fulbright fellowship which enabled him to work in immunology at Stanford California. In 1999 he returned to the UK as the first CRUK senior clinical fellow and became a senior lecturer at University of Southampton and subsequently a personal chair in 2003. In 2004 he was appointed Professor of Targeted Therapy and Oncology at University of Manchester and leads the translational Targeted Therapy Group, Cancer Research UK Manchester Institute. The translational research programme is based around radiotherapy and immunotherapy combinations, funded by CRUK programme grant. He chaired and UK NCRI Clinical and Translational radiotherapy group from 2010-2013 and remains on the steering committee. He has published extensively and was awarded the cancer researcher of the year by university of Manchester in 2012, and subsequently the researcher of the year for the Faculty of medical and Life sciences in 2013. He led the radiotherapy related research group of the Manchester Cancer Research Centre from 2007-2016, overseeing a large increase in research staff. He is currently Head of Division of Cancer Sciences at the University of Manchester, Manchester Academic Health Sciences Centre overseeing over 180 academic staff.